International Clinical Trial: A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07291076) titled 'A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)' on Dec. 17, 2025.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Bristol-Myers Squibb

Condition: Hepatocellular Carcinoma (HCC)

Intervention: Drug: Pumitamig Drug: Ipilimumab Drug: Atezolizumab

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollm...